
BiotechTV - News
BiotechTVAudio
- Format:
- Podcast
- New episodes:
- Daily
- Typical length:
- about 10 minutes
- Latest episode:
About this show
This is the primary news channel of BiotechTV where you will find on the ground reporting by our journalists from biotech hubs throughout the world.
Covers: biotechnology, pharmaceutical industry, biotech investing, clinical trials, drug approval, gene editing, neurodegenerative disease, immunology drugs
Show details and episodes come from the publisher's public feed at anchor.fm. Last updated . Names, artwork and text belong to their publishers.
Recently on this show
Summary of recent episodes, drawn from the publisher's feed.
BiotechTV's news feed offers on-the-ground reports from biotech hubs around the world. Recent episodes cover Jefferies London 2026 interviews with executives from Protagonist, Valneva, Generate Biomedicines and Intellia, plus Nektar's atopic dermatitis work and Sofinnova's new European fund.
Cosmos
Similar in subject
- Pharmaceutical Executive
Both cover: drug approval, pharmaceutical industry, clinical trials - BioTech Nation ... with Dr. Moira Gunn
Both cover: pharmaceutical industry, biotechnology - Biotech Hangout
Both cover: biotech investing, clinical trials
Similar shows
Explore more
Episodes
Jefferies London 2026: The phase 3 OPERA-01study of Olema's CERAN + SERD, palazestrant, is setting up to be one of biotech's key readouts and is quickly approaching and scheduled to read in 1Q27
· 11 min
CEO Sean Bohen reminds us of the mechanism and the design of this monotherapy study, which is in the 2/3 line ER+/HER2 metastatic breast cancer setting. He also discusses why he believes the OPERA-02 study in 2nd line in combo with a CDK 4/6 can succeed where a competitor failed earlier this year.
Not rated yetJefferies London 2026: Marea Therapeutics' CEO Josh Lehrer describes the ANGPTL4 target for targeting triglycerides (Marea is first in class) and compares and contrasts it to ANGPTL3 and APOE3
· 9 min
The company recently presented phase 2b data at AHA and published in NEJM. Dr. Lehrer also discusses the company's acromegaly program, and more.
Not rated yetJefferies London 2026: A top biotech CEO (Roivant's Matt Gline) and top investor (Affinity Asset Advisors' Patrick Nosker) talk running biotech companies and investing in them
· 19 min
They discuss Roivant's structure and programs (a top holding of Affinity's) and how different investors view companies different ways. Plus, the ups and downs of biotech, and why it is rare for smaller biotech companies to grow into larger entities over the long run.
Not rated yetJefferies London 2026: With two FDA filings under review and other programs in late stage, Praxis is in a pivotal moment - CEO Marcio Souza updates us on all the moving pieces
· 14 min
He shares an update on the ulixacaltamide and relutrigine filings, and how he thinks about potential commercialization opportunities. Plus, late stage readouts to watch out for.
Not rated yetJefferies London 2026: CRISPR Therapeutics CEO Sam Kulkarni walks us through the company's increasingly advancing pipeline, which includes an siRNA
· 16 min
He discusses ANGPTL3 in cardiology and allo CAR-T, both of which recently had data at medical meedings. Plus the idea behind branching out to siRNA, which targets FXI for thrombotic conditions.
Not rated yetJefferies London 2026: Protagonist Therapeutics' CEO Dinesh Patel discusses the launch of ICOTYDE, and the company's pipeline, which is well funded now due to commercial success
· 11 min
He comments on the early days of JNJ's ICOTYDE launch, developing an optimized IL-17, the obesity space, and more.
Not rated yetJefferies London 2026: Valneva CEO Thomas Lingelbach shares an update on the status of the company's Lyme disease program (partnered with Pfizer) and more pipeline projects
· 12 min
He discusses the regulatory status of Lyme disease, which hit on secondary enpoints in its phase three trial but narrowly missed the primary. Plus, updates on chikungunya and shigella.
Not rated yetJefferies London 2026: Generate Biomedicines' CEO Mike Nally describes the rationale behind a recent CAR-T deal with Anthropic, updates us on the company's TSLP, and more
· 10 min
He describes the win-win nature of working with Anthropic, which is related to redesigning CAR T-Cell Signaling. Plus, he discusses room for improvement in the TSLP space and why he believes Generate's candidate could be best in class.
Not rated yetJefferies London 2026: Nuvation Bio Founder & CEO David Hung shares an update on the launch of IBTROZI (next-gen ROS1 inhibitor and follow-on pipeline projects
· 9 min
He discusses the launch and his thoughts on any future copetitors in the space. Plus an update on the mIDH1 inhibitor safusidenib, and a drug-drug interaction platform that was the basis for founding the company.
Not rated yetJefferies London 2026: Intellia is currently in front of FDA for the potential approval of the first in vivo (in the body) CRISPR gene editing therapy - it is for hereditary angioedema
· 9 min
President & CEO John Leonard discusses the program and compares and contrasts it to more traditional medicines. He also provides an update on the company's transthyretin (ATTR) amyloidosis with cardiomyopathy (ATTR-CM) program.
Not rated yetJefferies 2026: Nektar Therapeutics has Rezpeg moving full speed ahead in atopic dermatitis and alopecia (and beyond) - the Head of R&D shares learnings about its mechanism
· 11 min
Jonathan Zalevsky describes how learnings from the phase 2 AD trial have helped with the study design of three phase 3 studies - and the latest on alopecia. He emphasizes how the company seems to be seeing a deepening of responses from this Treg targeting mechanism over time.
Not rated yetJefferies 2026: Sofinnova Partners announced today a new $815M fund today that will invest in mostly later stage European companies
· 10 min
Managing Partner Graziano Seghezzi tells us about the new fund and what it will invest in, and comments on the environment for European biotech today.
Not rated yetJefferies London: While its in the middle of the closely watched Attruby launch, BridgeBio has two other medicines in front of FDA and another big phase 3 readout scheduled for later next year
· 9 min
Founder & CEO Neil Kumar shares his take on how the Attruby launch is going, and also talks Limb-girdle muscular dystrophy type 2I/R9, achondroplasia, and hypoparathyroidism.
Not rated yetSTIFEL 2026: Trace Neuroscience believes that a breakthrough in ALS will be due to restoring expression of a protein called UNC13A, which most ALS patients don't have sufficient due to genetic factors
· 8 min
Co-Founder and CEO Eric Green explains the role of UNC13A, and how UNC13A mRNA is improperly spliced for most ALS patients. Trace is currently running a UK/EU phase 1 study of its antisense oligonucleotide that aims to restore expression, and also concurrently an investigator led study in China.
Not rated yetSTIFEL 2026: Oruka's IL-23p19 is showing strong efficacy in phase 2 studies compared to existing products and could be dosed as little as once or twice a year - a key update will read next month
· 11 min
CEO Lawrence Klein describes the data that has been seen so far (clearance in the 60% range at 16 weeks) and previews with upcoming 52 week data that will be coming in December. Plus, how the company is thinking about phase 3 design, and other assets in the pipeline.
Not rated yetStifel's Tim Opler on the state of biotech
· 9 min
Ahead of a 100+ slide "State of Biotech" report he is publishing tomorrow, he discusses the impact of Washington on biotech, how the sector has been trading lately, China, M&A and a lot more
Not rated yetSTIFEL 2026: ProMIS Neurosciences has an early, yet important Alzheimer's trial scheduled to read out over the coming months
· 18 min
CEO Neil Warma describes ProMIS's approach of targeting amyloid beta oligomers as opposed to the plaques. He explains how so far they have avoided the ARIA (brain swelling) seen with other Alzheimer's treatments and discusses what the company hopes to see from this phase 1b study. Plus, comments on the recent failure of another company in this space.
Not rated yetSTIFEL 2026: With expertise in the next generation of GPCR development, Septerna will have initial in human data on its oral PTH19 agonist for hypoparathyroidism in Q1
· 9 min
Co-Founder & CEO Jeff Finer walks us through the company's GPCR discovery platform, and discusses, this lead program, a new target (TSHR) they just named in Grave's disease and thyroid eye disease, and the company's work in obeisty with partner Novo Nordisk.
Not rated yetSTIFEL 2026: Rapport Therapeutics' CEO Abe Ceesay highlights the company's recent phase 2 success for RAP-219 in bipolar mania and discusses the next steps ahead
· 8 min
He describes the company's precision mechanism, and discussions they will have with FDA before starting phase 3 trials in this indicuation next year. Plus, previewing long-term data that will be out soon in epilepsy.
Not rated yetStifel's Head of Global Equity Capital Markets Seth Rubin shares his take on the state of biotech and the current environment for companies to raise money
· 5 min
He says that markets have taken a pause but he believes they are healthy and not broken, and he is optimistic about the future.
Not rated yet